FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1700218291> ?p ?o ?g. }

• W1700218291 endingPage "241" @default.
• W1700218291 startingPage "231" @default.
• W1700218291 abstract "Despite multimodal approaches to treatment, postpartum hemorrhage (PPH) is a life-threatening condition whose incidence continues to rise. In developing areas, such as sub-Saharan Africa, PPH is the leading cause of maternal mortality. Tranexamic acid (TXA) is a possible prophylactic treatment for the prevention of PPH. We performed a systematic review and meta-analysis of randomized trials comparing prophylactic TXA vs placebo or no treatment in term parturients to quantify the effects of prophylactic TXA administration on peripartum bleeding outcomes. The meta-analysis was performed using a random-effects model. The outcomes assessed were (i) incidence of PPH, (ii) mean blood loss (in milliliters) within 24hours, (iii) incidence of red blood cell transfusion within 24hours, (iv) use of additional uterotonics, (v) minor side effects (ie, nausea, vomiting, headache, etc), (vi) major venous thromboembolism, (vii) length of hospital stay, and (viii) mortality. Eighteen trials (3846 subjects) were included in the quantitative analysis, with 1935 patients receiving TXA. The studies were of poor to moderate quality. Prophylactic TXA administration was associated with a decreased incidence of PPH after delivery (odds ratio [OR], 0.32; 95% confidence interval [CI], 0.17-0.59; P = .0006), a reduction in mean blood loss by 149.1mL (95% CI, 112.9-185.2; P < .00001), and a reduction in red blood cell transfusions (OR, 0.28; 95% CI, 0.15-0.49; P < .00001) while also being associated with a reduction in the use of additional uterotonics (OR, 0.45; 95% CI, 0.30-0.66; P < .00001). Minor side effects were more common in those who received TXA (OR, 2.51; 95% CI, 1.69-3.74; P < .00001). There appeared to be no increased risk of venous thromboembolism and no difference in length of hospital stay associated with TXA use. Although prophylactic TXA administration may be associated with improved peripartum bleeding, existing evidence is insufficient for any definitive recommendations secondary to the poor to moderate quality of the literature. A large well-designed, methodologically sound, randomized controlled trial is needed to better delineate the true effect size and address potential safety concerns." @default.
• W1700218291 created "2016-06-24" @default.
• W1700218291 creator A5035328124 @default.
• W1700218291 creator A5049712798 @default.
• W1700218291 date "2015-10-01" @default.
• W1700218291 modified "2023-09-26" @default.
• W1700218291 title "Prophylactic Use of Tranexamic Acid for Postpartum Bleeding Outcomes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials" @default.
• W1700218291 cites W1593572830 @default.
• W1700218291 cites W1973459687 @default.
• W1700218291 cites W1985810044 @default.
• W1700218291 cites W1991392423 @default.
• W1700218291 cites W2008759928 @default.
• W1700218291 cites W2016537088 @default.
• W1700218291 cites W2017268487 @default.
• W1700218291 cites W2033899745 @default.
• W1700218291 cites W2052885488 @default.
• W1700218291 cites W2059519865 @default.
• W1700218291 cites W2061152996 @default.
• W1700218291 cites W2065150133 @default.
• W1700218291 cites W2067087790 @default.
• W1700218291 cites W2097670119 @default.
• W1700218291 cites W2100580681 @default.
• W1700218291 cites W2101141558 @default.
• W1700218291 cites W2107339086 @default.
• W1700218291 cites W2111482516 @default.
• W1700218291 cites W2119635589 @default.
• W1700218291 cites W2147479802 @default.
• W1700218291 cites W2162249417 @default.
• W1700218291 cites W2163813007 @default.
• W1700218291 cites W2171542172 @default.
• W1700218291 cites W2315310005 @default.
• W1700218291 cites W2320862607 @default.
• W1700218291 cites W4375906044 @default.
• W1700218291 cites W4375906097 @default.
• W1700218291 cites W1978106149 @default.
• W1700218291 cites W3143398651 @default.
• W1700218291 doi "https://doi.org/10.1016/j.tmrv.2015.07.002" @default.
• W1700218291 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26282735" @default.
• W1700218291 hasPublicationYear "2015" @default.
• W1700218291 type Work @default.
• W1700218291 sameAs 1700218291 @default.
• W1700218291 citedByCount "48" @default.
• W1700218291 countsByYear W17002182912016 @default.
• W1700218291 countsByYear W17002182912017 @default.
• W1700218291 countsByYear W17002182912018 @default.
• W1700218291 countsByYear W17002182912019 @default.
• W1700218291 countsByYear W17002182912020 @default.
• W1700218291 countsByYear W17002182912021 @default.
• W1700218291 countsByYear W17002182912022 @default.
• W1700218291 countsByYear W17002182912023 @default.
• W1700218291 crossrefType "journal-article" @default.
• W1700218291 hasAuthorship W1700218291A5035328124 @default.
• W1700218291 hasAuthorship W1700218291A5049712798 @default.
• W1700218291 hasConcept C120665830 @default.
• W1700218291 hasConcept C121332964 @default.
• W1700218291 hasConcept C126322002 @default.
• W1700218291 hasConcept C141071460 @default.
• W1700218291 hasConcept C142724271 @default.
• W1700218291 hasConcept C156957248 @default.
• W1700218291 hasConcept C168563851 @default.
• W1700218291 hasConcept C204787440 @default.
• W1700218291 hasConcept C27081682 @default.
• W1700218291 hasConcept C2779637338 @default.
• W1700218291 hasConcept C2780014101 @default.
• W1700218291 hasConcept C2780580376 @default.
• W1700218291 hasConcept C2780852908 @default.
• W1700218291 hasConcept C2991743468 @default.
• W1700218291 hasConcept C42219234 @default.
• W1700218291 hasConcept C44249647 @default.
• W1700218291 hasConcept C61511704 @default.
• W1700218291 hasConcept C71924100 @default.
• W1700218291 hasConcept C95190672 @default.
• W1700218291 hasConceptScore W1700218291C120665830 @default.
• W1700218291 hasConceptScore W1700218291C121332964 @default.
• W1700218291 hasConceptScore W1700218291C126322002 @default.
• W1700218291 hasConceptScore W1700218291C141071460 @default.
• W1700218291 hasConceptScore W1700218291C142724271 @default.
• W1700218291 hasConceptScore W1700218291C156957248 @default.
• W1700218291 hasConceptScore W1700218291C168563851 @default.
• W1700218291 hasConceptScore W1700218291C204787440 @default.
• W1700218291 hasConceptScore W1700218291C27081682 @default.
• W1700218291 hasConceptScore W1700218291C2779637338 @default.
• W1700218291 hasConceptScore W1700218291C2780014101 @default.
• W1700218291 hasConceptScore W1700218291C2780580376 @default.
• W1700218291 hasConceptScore W1700218291C2780852908 @default.
• W1700218291 hasConceptScore W1700218291C2991743468 @default.
• W1700218291 hasConceptScore W1700218291C42219234 @default.
• W1700218291 hasConceptScore W1700218291C44249647 @default.
• W1700218291 hasConceptScore W1700218291C61511704 @default.
• W1700218291 hasConceptScore W1700218291C71924100 @default.
• W1700218291 hasConceptScore W1700218291C95190672 @default.
• W1700218291 hasIssue "4" @default.
• W1700218291 hasLocation W17002182911 @default.
• W1700218291 hasLocation W17002182912 @default.
• W1700218291 hasOpenAccess W1700218291 @default.
• W1700218291 hasPrimaryLocation W17002182911 @default.
• W1700218291 hasRelatedWork W2005921017 @default.
• W1700218291 hasRelatedWork W2040233681 @default.

• next